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Abstract
Objective To develop and validate risk algorithms (QBleed) for estimating
the absolute risk of upper gastrointestinal and intracranial bleed for
patients with and without anticoagulation aged 21-99 years in primary
care.
Design Open cohort study using routinely collected data from general
practice linked to hospital episode statistics data and mortality data
during the five year study period between 1 January 2008 and 1 October
2013.
Setting 565 general practices in England contributing to the national
QResearch database to develop the algorithm and 188 different
QResearch practices to validate the algorithm. All 753 general practices
had data linked to hospital episode statistics and mortality data at
individual patient level.
Endpoint Gastrointestinal bleed and intracranial bleed recorded on
either the linked mortality data or the linked hospital records.
ParticipantsWe studied 4.4 million patients in the derivation cohort with
16.4 million person years of follow-up. During follow-up, 21 641 patients
had an incident upper gastrointestinal bleed and 9040 had an intracranial
bleed. For the validation cohort, we identified 1.4 million patients
contributing over 4.9 million person years of follow-up. During follow-up,
6600 patients had an incident gastrointestinal bleed and 2820 had an
intracranial bleed. We excluded patients without a valid Townsend score
for deprivation and those prescribed anticoagulants in the 180 days
before study entry.
Risk factors Candidate variables recorded on the general practice
computer system before entry to the cohort, including personal variables
(age, sex, Townsend deprivation score, ethnicity), lifestyle variables
(smoking, alcohol intake), chronic diseases, prescribed drugs, clinical
values (body mass index, systolic blood pressure), and laboratory test
results (haemoglobin, platelets). We also included previous bleed
recorded before entry to the study.
Results The final QBleed algorithms incorporated 21 variables. When
applied to the validation cohort, the algorithms in women explained 40%
of the variation for upper gastrointestinal bleed and 58% for intracranial
bleed. The corresponding D statistics were 1.67 and 2.42. The receiver
operating curve statistic values were 0.77 and 0.86. The sensitivity values
for the top 10th of men and women at highest risk were 38% and 51%,
respectively. There were similar results for men.
Conclusion The QBleed algorithms provided valid measures of absolute
risk of gastrointestinal and intracranial bleed in patients with and without
anticoagulation as shown by the performance of the algorithms in a
separate validation cohort. Further research is needed to evaluate the
clinical outcomes and the cost effectiveness of using these algorithms
in primary care.
Introduction
Anticoagulants are used in the prevention and treatment of
venous thromboembolism. They are also used to reduce risk of
ischaemic stroke,1 especially among patients with atrial
fibrillation. The use of anticoagulants is likely to increase in
future, especially since guidelines from the UKNational Institute
for Health and Care Excellence encourage more systematic
identification of patients at high risk of venous
thromboembolism or stroke who might benefit from
anticoagulation. For example, in 2010 NICE issued new
guidance to improve the prevention of venous thromboembolism
for patients, using cost effective interventions.2 In January 2014
NICE issued draft guidance on the management of atrial
fibrillation, which included assessment of the risks of stroke as
well as the risks and benefits associated with anticoagulation.3
New tools now exist to quantify the absolute risk of thrombosis4
as well as those at risk of ischaemic stroke in primary care,
including patients with atrial fibrillation.5 Although the risk of
stroke in patients with atrial fibrillation can be reduced by
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anticoagulation,1 many patients with atrial fibrillation are not
currently prescribed anticoagulation even though it is
incentivised in the general practice Quality and Outcomes
Framework.6 This may reflect concerns about monitoring, or
uncertainties about the potential balance of risks and benefits
for an individual patient, including the potential adverse
haemorrhagic effects of traditional anticoagulants such as
warfarin. Novel oral anticoagulants (factor Xa inhibitors and
direct thrombin inhibitors) exist that have the advantage of not
requiring regular international normalisation ratio (INR) blood
test monitoring.7 Data on safety and efficacy of the novel
anticoagulants is still accumulating. However, a recent
meta-analysis of three randomised controlled trials8 reported
that the new anticoagulants are more effective at reducing all
cause stroke and systemic embolism (relative risk 0.78, 95%
confidence interval 0.67 to 0.92) in people with atrial fibrillation
compared with warfarin. However, data on risks of major
bleeding (0.88, 0.71 to 1.09) were inconclusive,8 with a
suggestion of an increased risk of gastrointestinal bleeding (1.25,
0.91 to 1.72) compared with warfarin.8Quantifying the absolute
risk of bleed for an individual receiving anticoagulation
treatment is important because it can help clinicians identify
patients for whom the benefit of anticoagulation outweighs the
risk of bleed, help inform the discussion with patients about the
risks and benefits of anticoagulation, and allow clinicians to
monitor more carefully patients at high risk to help reduce their
risk. For example, this could be achieved by modifying known
risk factors for bleed, including avoidance of the use of
concurrent drugs known to increase the risk of bleed, such as
non-steroidal anti-inflammatory drugs (NSAIDs) and
antidepressants.9
Several clinical risk prediction rules have been developed to
assess the risk of bleed. Among the first were the
HEMOR2RHAGES,
10 ATRIA scores,11 and RIETE and OBRI
scores.12 More recently the HAS-BLED score13 has been
developed and is recommended in the European Society of
Cardiology guidelines.14 HAS-BLED has several advantages
compared with previous scores as it does not require information
unlikely to be available in clinical practice, such as genetic
information. It has also has out-performed previous scores in
identifying clinically relevant bleeding.15 The populations used
to develop HAS-BLED, as with HEMOR2RHAGES,
10 are
unlikely to be representative of patients in UK primary care,
having been recruited through an American insurance scheme10
or through secondary care as part of a clinical trial.11 13 The
studies are based on small cohorts of patients with low numbers
of events. The resulting scores are implemented using simple
counting systems, do not include some important risk factors
for bleed, and do not give an absolute risk of bleed. Although
including more risk factors within a risk score generally
improves risk stratification, it also makes tools such as
HAS-BLED increasingly cumbersome to use in everyday
clinical practice. Limitations of the ATRIA scores have been
highlighted,16 including use of a cohort that had already received
anticoagulants, exclusion of patients with risk factors, and
counterintuitive results, including an apparent protective effect
of previous bleed and concurrent use of antiplatelet treatment.16
We developed and validated a new set of risk prediction
algorithms to predict risk of gastrointestinal and intracranial
bleed in new users of anticoagulants (rather than existing users).
We wanted to develop algorithms that quantify absolute risk of
bleed, which can be communicated to patients to aid decision
making in the consultation, automatically populated from the
patients record and integrated into general practice computer
systems, and updated readily over time, as the pattern of
prescribing of both anticoagulant drug classes may change.
Methods
Study design and data source
We conducted a cohort study of a large primary care population
using version 38 of the QResearch database (www.qresearch.
org). QResearch is a large validated primary care electronic
database containing the health records of 14 million patients
registered from 753 general practices using the Egton Medical
Information System (EMIS) computer system.17 Practices and
patients contained on the database are nationally representative18
and similar to those on other primary care databases using other
clinical software systems.19We included all QResearch practices
in England once they had been using their current EMIS system
for at least a year (to ensure completeness of recording of
morbidity and prescribing data), randomly allocating three
quarters of practices to the derivation dataset and one quarter
to the validation dataset.
Overall cohort selection
We identified an open cohort of patients aged 21-99 years at
the study entry date, drawn from patients registered with eligible
practices between 1 January 2008 and 1October 2013.We used
an open, rather than closed, cohort design, as this allows patients
to enter the population throughout the whole study period rather
than require registration on 1 January 2008, thus better reflecting
the realities of routine general practice. We excluded patients
without a valid postcode related Townsend deprivation score,
and existing users of anticoagulants by excluding those
prescribed anticoagulants in the 180 days before their study
entry date. To helpminimise potential biases we used an incident
user design.20
For each patient we determined an initial entry date to the cohort,
which was the latest of the following dates: 21st birthday, date
of registration with the practice plus one year, date on which
the practice computer system was installed plus one year, and
the beginning of the study period (1 January 2008). For patients
who had started an anticoagulant after their initial entry date,
we assigned an index entry date that was the date of their first
prescription of the anticoagulant during the study period.
We censored patients at the earliest date of the first upper
gastrointestinal haemorrhage or intracranial haemorrhage, death,
deregistration with the practice, last upload of computerised
data, three months after their last prescription for anticoagulants
(if applicable), five years after their study entry date, or the
study end date (1 October 2013). For intermittent users of
anticoagulants, if there was a gap of more than three months
between the end of one prescription and the start of the next,
we censored them after three months from the start of the gap
even if the patient had future prescriptions. Patients who
switched anticoagulants during the study period were censored
one month after their last prescription before the switch.
Outcomes
Our two primary outcomes were incident gastrointestinal bleed
and incident intracranial bleed occurring within five years of
study entry. We used ICD-10 (international classification of
diseases, 10th revision) codes to identify events that were
recorded on either the linked hospital record or the mortality
record. Supplementary table 1 lists the ICD-10 codes used for
upper gastrointestinal bleeding and supplementary table 2 the
codes used for intracranial bleed. Upper gastrointestinal bleed
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was defined as any upper gastrointestinal ulcer with perforation,
bleed, or both; melena; haematemesis; laceration with bleed;
varices with bleed; haemorrhagic gastritis; and other unspecified
gastrointestinal bleeds. Intracranial bleed was defined as
subarachnoid haemorrhage, intracerebral haemorrhage, subdural
or extradural haemorrhage, and other unspecified intracranial
bleeds.
The QResearch database is linked at individual patient level to
both the hospital admissions data and the Office for National
Statistics mortality records using a project specific
pseudonymised National Health Service number. The recording
of NHS numbers is valid and complete for 99.8% of patients
with records on QResearch, 99.9% for Office for National
Statistics mortality records, and 98.6% for hospital admissions
records.21 22 We defined patients as having the outcome of
interest if there was a record of the relevant ICD-10 code in
either their hospital record or their linked mortality record. For
example, for a patient to be classified as having been admitted
to hospital due to bleeding, the ICD-10 code would be recorded
as the primary diagnosis in the hospital admissions data.
Similarly for a patient to have been considered to have died due
to bleeding, the relevant ICD-10 code would be recorded as
either the primary or the underlying cause of death in the Office
for National Statistics mortality record. We did not include
events that were recorded on the general practice record but not
on either the hospital or mortality record as we wanted to ensure
the events were likely to represent severe bleeding.
We separately quantified the risk of upper gastrointestinal bleed
and intracranial bleed, as has been done in relevant clinical
trials.8 These two events are potentially life threatening or life
changing and may be preventable. We initially considered
having a more general outcome of “any haemorrhagic event”
but decided against this given the disparate nature of the events,
the rarity with which some occur, the lack of relevant ICD-10
codes for some outcomes, and the difficulty of applying
definitions requiring clinical adjudication to routinely collected
data.
Exposure
The primary exposure of interest was use of anticoagulants,
including warfarin, phenindione, dabigatran, rivaroxaban, or
apixaban. We identified new users of anticoagulants during the
study period by identifying those with at least one prescription
issued after the date of initial entry to the study. We excluded
patients who had been prescribed one or more prescriptions in
the past 180 days before their study entry date. The remaining
patients were classified as non-users of anticoagulants.
Predictor variables for consideration
Using similar definitions where relevant we compiled a list of
risk factors (box) based on the September 2013 edition of the
British National Formulary, literature, and existing risk
prediction scores.
For clinical values, we used the most recently recorded before
entry to the cohort (box). For new users of anticoagulants, we
used the values recorded before they started anticoagulants.We
identified medical conditions based on the patient’s primary
care record, using standard definitions of Read codes where
available. We considered the conditions to be present if they
were entered in the patients’ record before entry to the cohort.
We identified new users of anticoagulants and users of other
drugs thought to increase the risk of bleeding or that interact
with anticoagulants (box). To qualify for being exposed to the
relevant drug at study entry, participants had to have at least
two prescriptions, with the most recent one within the preceding
28 days before entry to the cohort.
Derivation of the models
We used published methods to derive and validate models that
could be applied to new users of anticoagulants.25 26 As in
previous similar studies, we decided a priori to derive separate
models in men and women since the predictors and their
weightings are likely to be different. We therefore derived four
models in total—gastrointestinal bleed and intracranial bleed
for men and a corresponding set for women. We used multiple
imputation to replace missing values for body mass index,
systolic blood pressure, smoking, and alcohol intake, and used
these values in our main analyses.27-30 We carried out five
imputations. We used Cox’s proportional hazards models to
estimate the coefficients for each risk factor for men and women
separately, using Rubin’s rules to combine the results across
the imputed datasets. We used fractional polynomials to model
non-linear risk relations with continuous variables.31 We used
backward selection procedures to eliminate variables, using a
P value of 0.01 to obtain parsimonious models. We focused on
predictor variables that have a clinical face validity and are
included in similar scores and those that have a hazard ratio of
<0.85 or >1.15 (for categorical exposures), selecting those that
met these criteria for inclusion in the final model.
We examined interactions between predictor variables and age.
We also tested for interactions between anticoagulants and drugs
thought to increase the risk of a bleed, such as antiplatelets and
other drugs listed previously.We included significant interaction
terms in the final models where these were plausible.
We took the regression coefficients for each variable from the
final models and used these as weights, which we combined
with the baseline survivor function for each outcome evaluated
at each of 1-5 years to derive absolute risk equations at each
years’ follow-up.
Validation of the models
We applied each of the models obtained from the derivation
cohort to the validation cohort and calculated predicted risks
for each patient and measures of discrimination (D statistic32
and area under the receiver operating characteristic curve
statistic) and calibration (comparing observed risk at five years
with mean predicted risks by 10th of predicted risk), and
displayed these as plots. Discrimination is the ability of the risk
prediction model to differentiate between patients who do and
do not experience an event during the study. This can be
quantified by calculating the area under the receiver operating
characteristic curve statistic; where a value of 1 represents
perfect discrimination. The D statistic32 is also a measure of
discrimination that is specific to censored survival data. As with
the receiver operating characteristic curve, higher values indicate
better discrimination.We also calculated an R2measure specific
to censored survival data—it measures explained variation, and
higher values indicate more variation explained.33
We used the predicted risks in the QResearch validation cohort
to define a threshold for the top 10% of patients at highest
predicted risk of bleed. We carried out a separate analysis
restricted to patients in the validation cohort with atrial
fibrillation. We used all the available data on the QResearch
database to maximise the power and also the generalisability
of the results. We used STATA (version 13) for all analyses.
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Risk factors associated with risk of bleeding
Personal and life style
• Age (years) at study entry23
• Self assigned ethnicity: white or not recorded, Indian, Pakistani, Bangladeshi, other Asian, Black African, Black Caribbean, Chinese, other (including
mixed)
• Smoking status: non-smoker, former smoker, light smoker (<10 cigarettes/day), moderate smoker (10-19 cigarettes/day), heavy smoker (≥20
cigarettes/day)
• Deprivation: Townsend score23 24
• Alcohol intake (units/day): none, <1, 1 or 2, 3-6, 7-9, >913
Clinical values (most recent before study entry)
• Body mass index
• Systolic blood pressure
• Haemoglobin <110 g/L
• High or low platelet count (<150/μL or >480/μL)
Medical conditions thought to increase the risk of bleed
• Treated hypertension13: (recorded diagnosis of hypertension and a current prescription for at least one antihypertensive)
• Atrial fibrillation or flutter (including paroxysmal atrial fibrillation)
• Chronic renal disease13: Read code indicating glomerular filtration rate <60 mL/min or recorded diagnosis of major renal disease, including renal
transplant or dialysis
• Chronic liver disease or chronic pancreatitis13: including cirrhosis, liver failure, liver fibrosis, portal hypertension, chronic hepatitis, autoimmune hepatitis,
and chronic pancreatitis
• Type 1 or type 2 diabetes (including diagnosis of diabetes or treatment with oral hypoglycaemic agents or insulin)
• Ischaemic stroke or transient ischaemic attack13
• Congestive cardiac failure (including left ventricular failure, right heart failure, pulmonary oedema)
• Venous thromboembolism (including pulmonary embolism or deep vein thrombosis)
• Cancer (any diagnosis of cancer, excluding non-melanoma skin cancer)
• Peptic ulcer (including gastric, oesophageal, or duodenal ulceration)
• Oesophageal varices or arteriovenous malformation
• Previous bleed recorded in the general practice record (including intracranial, upper gastrointestinal, haematuria, or haemoptysis)
Drugs thought to increase bleeding risk or interact with anticoagulants
• Anticoagulants (new users)
• Antiplatelets: aspirin, dipyramidole, clopidogrel13
• Non-steroidal anti-inflammatory drugs
• Corticosteroids
• Statins
• Antidepressants9
• Rifampicin
• Carbamazepine
• Phenytoin
• Quinidine
• Verapamil
• Clarithromycin
• Amiodarone
• Chloramphenicol
• Antifungals
Results
Practices and patients
Overall, 753 practices in England met our inclusion criteria and
all had been using their current computer system for at least one
year. Of these, 565 were randomly assigned to the derivation
dataset and 188 to the validation dataset. We identified 4 437
419 patients aged 21-99 years in the derivation cohort. Of these,
7870 (0.2%) had a missing Townsend score and 50 698 (1.2%)
had at least one prescription for anticoagulants in the 180 days
before study entry, leaving 4 378 851 eligible patients for
analysis. We identified 1 373 253 patients aged 21-99 years in
the validation cohort. Of these, 2041 (0.1%) had a missing
Townsend score and 15 022 (1.1%) had at least one prescription
for anticoagulants in the 180 days before their study entry date,
leaving 1 358 231 eligible patients for analysis.
Table 1⇓ shows the characteristics of eligible patients prescribed
warfarin, novel anticoagulants, and neither drug for both the
derivation and validation cohort recorded before entry to the
cohort. Of the 52 485 patients in the derivation cohort prescribed
warfarin, 23% had a previous bleed. Of the 1641 patients
prescribed novel anticoagulants, 27% had a previous bleed.
Overall, 27% of patients prescribed warfarin had concurrent
prescriptions for non-steroidal anti-inflammatory drugs, 11%
for corticosteroids, and 37% for antiplatelets. The corresponding
figures for patients prescribed novel anticoagulants were 39%,
10%, and 35%. Although the validation cohort was drawn from
an independent group of practices, the baseline characteristics
were generally similar to those for the derivation cohort.
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Incidence rates of bleed
Table 2⇓ shows the incidence of both types of bleed during
follow-up in patients prescribed warfarin, new anticoagulants,
or neither drug.
Overall in the derivation cohort, we identified 21 641 patients
with an incident upper gastrointestinal bleed and 9040 with an
intracranial bleed, arising from 16.4 million person years of
observation. The crude incidence rate for upper gastrointestinal
bleed was 1.32 per 1000 person years. The crude incidence rate
for intracranial bleeds was 0.55 per 1000 person years.
We standardised incidence rates to the overall age distribution
of the derivation cohort. The age standardised incidence rate of
upper gastrointestinal bleed per 1000 person years was 1.34
(95% confidence interval 1.32 to 1.36) in patients not prescribed
anticoagulants, 5.83 (4.33 to 7.33) in those prescribed warfarin,
and 2.69 (0.36 to 5.03) in those prescribed new anticoagulants.
The corresponding figures for intracranial bleed per 1000 person
years were 0.55 (0.54 to 0.56), 1.89 (1.46 to 2.32), and 1.49
(1.27 to 2.86).
Model development
Upper gastrointestinal bleed
Table 3⇓ shows the models for upper gastrointestinal bleed in
men and women. Details of the fractional polynomial terms for
age and body mass index are given in the footnote of table 3
and in figure 1⇓. The final model included 20 variables in
addition to use of anticoagulants. These were age, body mass
index, Townsend score, smoking status, ethnicity, alcohol intake,
previous bleed, oesophageal varices, chronic liver disease or
pancreatitis, atrial fibrillation, venous thromboembolism,
congestive cardiac failure, treated hypertension, cancer, recent
abnormal platelet counts (<150/μL or >480/μL), and current
prescriptions for antiplatelets, non-steroidal anti-inflammatory
drugs, corticosteroids, antidepressants, and anticonvulsants
(phenytoin or carbamazepine).
At the mean age, there was a fourfold increased risk of upper
gastrointestinal bleed associated with new use of anticoagulants
in men (adjusted hazard ratio 4.43, 95% confidence interval
3.32 to 5.92) and in women (3.89, 2.75 to 5.49). The risk of
upper gastrointestinal bleed increased with age in both sexes
(fig 1). Two interactions were included in the final model, which
were between the age terms and anticoagulant use and between
age and previous bleed. Both of these indicated higher hazard
ratios for anticoagulant use and previous bleed among younger
patients compared with older patients (fig 1).
In terms of concurrent prescribed drugs, the risks associated
with antidepressants were higher than those associated with
non-steroidal anti-inflammatory drugs and antiplatelets. In
women, the adjusted hazard ratio for antidepressants was 1.57
(95% confidence interval 1.51 to 1.64) and for non-steroidal
anti-inflammatory drugs was 1.16 (1.11 to 1.21). There was a
suggestion of a dose response for both alcohol and smoking.
Heavy andmoderate smokers had higher risks than non-smokers
and former smokers. There was a “U shaped” effect for alcohol
intake, with lower risks associated with trivial, light, and
moderate alcohol consumption compared with none, and higher
risks associated with heavy and very heavy consumption.
Intracranial bleed
Table 4⇓ shows the adjusted hazard ratios and 95% confidence
intervals for the final model for intracranial bleed. The final
model included 15 variables in addition to use of anticoagulants,
which were age, bodymass index, Townsend deprivation score,
smoking status, ethnicity, alcohol intake, previous bleed,
oesophageal varices, chronic liver disease or pancreatitis, atrial
fibrillation, treated hypertension, recent abnormal platelet counts
(<150/μL or >480/μL), and current prescriptions for antiplatelets,
antidepressants, and anticonvulsants (phenytoin or
carbamazepine). The footnote of table 4 gives details of the
fractional polynomial terms for age and body mass index. One
interaction terms were included in the final model, which were
between the age terms and anticoagulant use.
At the mean age, there was around a fourfold increased risk of
intracranial bleed associated with new use of anticoagulants in
men (adjusted hazard ratio 3.99, 95% confidence interval 1.86
to 8.55) and in women (3.62, 1.25 to 10.49). The risk of
intracranial bleed increased with age in both sexes (fig 2⇓). The
age interaction terms indicated that middle agedmen andwomen
tended to have higher hazard ratios associated with
anticoagulation compared with younger and older patients (fig
2).
Calibration and discrimination in the
validation cohort
For the validation cohort, we identified nearly 1.4 million
patients contributing over 4.9 million person years of follow-up.
During follow-up, 6600 patients had an incident upper
gastrointestinal bleed and 2820 had an intracranial bleed. Table
5⇓ shows the performance of each model in the validation
cohort.
For the upper gastrointestinal bleed outcome, the algorithms
explained approximately 41% of the variation in women and
37% of the variation in men. The D statistic was 1.70 in women
and 1.57 in men. The receiver operating characteristic curve
value was 0.77 for women and 0.75 for men. For intracranial
bleed, the algorithms explained approximately 58% of the
variation in women and 53% of the variation in men. The D
statistic was 2.40 in women and 2.19 in men. The receiver
operating characteristic curve value was 0.85 for women and
0.81 for men.
To assist in the comparison with other bleeding risk scores we
repeated the validation restricting the sample to men and women
with atrial fibrillation (n=12 560) and we used the intracranial
bleed outcome, which is comparable to that used in validation
analyses of other scores.15 The receiver operating characteristic
curve statistic for men and women combined was 0.65 (0.61 to
0.69).
Table 6⇓ shows the performance statistics of both algorithms
in the full validation cohort for the 10% of men and women at
highest predicted risk of each outcome. For example, for the
10% of men and women at highest predicted risk of an
intracranial bleed (that is, those with a five year predicted risk
score of 0.7% or higher), the sensitivity was 51%, and the
observed risk at five years was 1.5%. For upper gastrointestinal
bleed, the corresponding sensitivity was 38%, with an observed
risk of 2.7% at five years.
Figure 3⇓ displays the predicted and observed risks of bleed at
five years across each 10th of predicted risk (1 representing the
lowest risk and 10 the highest risk) for each of the four models.
Overall the models were well calibrated.
Figure 4⇓ shows two clinical examples of using the web
calculator at www.qbleed.org to calculate the absolute risk of
bleed with and without anticoagulants in individual patients.
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Discussion
We developed and validated two models (collectively known
as the QBleed algorithms) to identify patients at high risk of
gastrointestinal or intracranial bleed. The QBleed algorithms
incorporate predictor variables that are associated with an
increased risk of haemorrhagic events, including
sociodemographic variables, lifestyle, morbidity, drugs, and
laboratory test results such as abnormal platelet function. The
algorithms can be applied to any adult in a primary care setting
regardless of whether they have had a previous bleed and have
the advantage of evaluating risk in new users of oral
anticoagulants, which is likely to be the highest risk period for
bleeding.
The QBleed algorithms are intended to help inform decisions
within the consultation about the risks and benefits of patients
in primary care using anticoagulants. For example, the doctor
can assess the patient’s five year risk of stroke using QStroke5
or five year risk of thrombosis using QThrombosis4 against the
risk of bleed with or without anticoagulation using QBleed. The
doctor and patient also can review factors that might ameliorate
the risks, such as amending concurrent drugs. Overall this could
help the doctor and patient assess whether the balance of risks
and benefits is likely to be favourable or not given the patient’s
profile.
The QBleed algorithms provide an estimate of absolute risk of
two types of bleed for each year for each of the next five years.
The algorithms are designed to be used before anticoagulant
treatment is started using information already available at the
time, rather than to guide the continuing use of anticoagulants,
taking into account changes in treatment during follow-up. The
algorithms to quantify risk of intracranial bleed performed better
than the algorithms to predict upper gastrointestinal bleed.
Comparison with other risk scores
We reviewed other clinical risk prediction tools designed to
help quantify risk of bleed among patients prescribed
anticoagulants, includingHEMOR2RHAGES,
10ATRIA, RIETE,
OBRI,12 and HAS-BLED,13 although these are all simple
counting systems rather than tools to quantify absolute risk as
in our study. They also predict a combined general “major
bleed” outcome, which is not directly comparable to our study
since they include events that cannot be identified from routinely
collected data. The HAS-BLED alogorithm is a scoring system
derived from a population of 3978 patients aged 18 or more
with atrial fibrillation who had 53 haemorrhagic events during
a one year follow-up period.13 The score includes the variables:
hepatic or renal disease; use of aspirin or non-steroidal
anti-inflammatory drugs or alcohol; older age (≥65 years);
previous bleed; and uncontrolled hypertension, stroke, and labile
international normalised ratio. The international normalised
ratio test is taken while a patient is prescribed warfarin, therefore
the HAS-BLED score is more applicable to patients with atrial
fibrillation already prescribed warfarin than to new users of
anticoagulants as in our study who may have additional
indications for anticoagulation. One of the key problems with
the HAS-BLED score is that the variables included in it nearly
always scored parallel to the stroke risk (for example, CHADS2)
score in patients with atrial fibrillation. This made it difficult
to assess whether the risk of stroke or the risk of bleeding was
higher. In contrast, QBleed and its associated risk scores
(QStroke5 andQThrombosis4 for assessing stroke and thrombosis
risk, respectively) use different variables, which are separately
weighted and so are likely to give better assessment of the
different risks. Also, HAS-BLED is a counting system resulting
in a score between 0 and 9 rather than a measure of absolute
risk of bleed as with QBleed. Although not directly comparable
to HAS-BLED, the receiver operating characteristic curve value
for QBleed (intracranial bleed) among patients with atrial
fibrillation was 0.65 (95% confidence interval 0.61 to 0.69) in
our validation cohort, which is slightly higher than the median
C statistic from six cohort studies for HAS-BLED (0.61, 0.59
to 0.62).3
HEMOR2RHAGES is another scoring system, which was
derived from a cohort of 3791 elderly patients aged 65-95 years
with atrial fibrillation participating in an American insurance
scheme.10 The study was small and included only 162
haemorrhagic events during follow-up. The score ranges from
0 to 12 and takes account of hepatic or renal disease, alcohol
misuse, cancer, older age (≥75 years), previous bleed, reduced
platelet count, hypertension, anaemia, excessive risk of falls,
stroke, and genetic polymorphism. We were unable to apply it
to our dataset as QResearch does not include some of the
relevant variables such as genetic information. A recent review
by the National Institute for Health and Care Excellence reported
that the median C statistic for HEMOR2RHAGES from four
cohort studies was 0.61 (95% confidence interval 0.56 to 0.65).3
Although these studies are not directly comparable to QBleed,
the C statistics presented tended to be lower than the receiver
operating characteristic curve value we report for QBleed
(intracranial bleed) in patients with atrial fibrillation (0.65, 0.61
to 0.69).
Incidence rates and predictor variables
The incidence rates of events and the predictor variables
included in our final models have good face validity compared
with the literature. For example, our crude rate of hospital
admission or death for upper gastrointestinal haemorhage (1.32
per 1000 person years) is similar to that reported by Button and
colleagues in a Welsh study (1.34 per 1000 person years).23 It
is marginally higher than the rates reported by Crooks and
colleagues24 (0.87 per 1000 person years) and Rockall and
colleagues34 (1.03 per 1000 person years), both of which used
slightly different definitions. Our crude incidence rate of
intracranial bleed (which includes intracerebral, subarachnoid
, intradural, and extradural bleed) was 0.55 per 1000 person
years, which is consistent with the incidence of intracerebral
and subarachnoid bleeds of 0.4 per 1000 person years reported
by Nilsson in Sweden35 and with the incidence rate for
intracerebral bleeds of 0.25 per 1000 reported in a systematic
review by Van Asch.36
We found that nearly all of the relevant available predictors
included in HEMOR2RHAGES
10 and HAS-BLED13 met the
inclusion criteria for incorporation into our models. We found
that increasing levels of material deprivation were associated
with higher risk of bleed, including upper gastrointestinal bleed,
supporting the findings of Button and colleagues.23 Similar to
Tata and colleagues, we found that antidepressants were
independently associated with an increased risk of upper
gastrointestinal bleed.9 For some variables, which were tested
but not included in our final model (such as rifampicin and
quinidine), there were too few patients exposed and too few
events to allow a robust analysis. We decided to include several
variables in the models (such as peptic ulcer and oesophageal
varices), although they have now been identified as a
contraindication to the new anticoagulants. This information
was published after the end of the study period and does not yet
apply to warfarin. One of the advantages of developing risk
tools using QResearch is that the risk model can be updated
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over time should new predictors be identified or existing
predictors lose relevance.
Thresholds
We have not provided definite comment on what threshold of
absolute risk should be used for intervention or avoiding
anticoagulants as that would require consideration of the balance
of risk and benefit for an individual and their choice and require
cost-effectiveness analyses, which are outside the scope of this
study. We have, however, provided analyses using the top 10%
of absolute risk as the threshold of risk, which can be used to
help inform future analyses. Sensitivity is important as it is a
measure of how well the algorithm performs in finding cases
that might be suitable for intervention. If the risk threshold is
set too high, then the sensitivity will be low and a large number
of patients with bleeds will be “missed” by the algorithm.
Conversely, a high risk threshold is likely to result in a higher
positive predictive value, which means a higher proportion of
those identified are likely to go on to have a bleed. So, at the
population level there is a balance to be struck between the
sensitivity and positive predictive value of the score, which
depends on the risk threshold selected, resources available, and
likely risks and benefits of the interventions.
At the individual level, we envisage that the doctor and patient
will review the absolute risk of intracranial or upper
gastrointestinal bleed with and without anticoagulation. They
can then compare this against the patient’s baseline risk of
having a stroke or thrombosis and potentially the expected
benefit to be derived from starting anticoagulation (although
this is outside the scope of the current paper). They can then
use this information to balance the estimated absolute
individualised risks and benefits to inform the decision about
anticoagulants.
Comparison between warfarin and new
anticoagulants
We were interested to be able to quantify risk separately for
new use of warfarin compared with new use of other
anticoagulants (dabigatran, rivaroxaban, apixaban, or
phenindione). However, it was apparent from initial analyses
that the numbers of patients prescribed these new drugs are as
yet insufficient as are the numbers of events over time to
quantify the effects as separate variables with the risk model.
We were able to compare the baseline characteristics of patients
prescribed each category of drug (table 1) and to calculate age
standardised incidence rates of events for our main outcomes
separately for warfarin compared with the novel anticoagulants
(table 2). The age standardised incidence rates of both types of
bleed were higher with warfarin than with the new
anticoagulants, but the confidence intervals overlapped. In light
of the announcement by the US Food and Drug Administration
on 30 December 2013,37 there is a need to further investigate
potential safety issues with the new anticoagulants once more
data are available. We plan to update the QBleed score when
sufficient data are available to undertake direct comparisons
between the older and newer agents, at which point we will be
able to decide whether they should be presented as separate or
combined variables.
Methodological considerations
The methods to derive and validate this model are the same as
for a range of other clinical risk prediction tools derived from
the QResearch database.4 25 26 38 39 The strengths and limitations
of the approach have already been discussed in detail,4 19 38 40-42
including information on multiple imputation of missing data.
In summary, key strengths include size, duration of follow-up,
and representativeness, and lack of selection, recall, and
respondent bias. UK general practices have good levels of
accuracy and completeness in recording clinical diagnoses and
prescribed drugs.43 We think our study has good face validity
since it was conducted in the setting where most patients in the
United Kingdom are assessed, treated, and followed up. Our
database has linked hospital and mortality records for nearly all
patients and is therefore likely to have picked up the majority
of severe bleeds requiring admission to hospital or resulting in
death thereby minimising ascertainment bias. We excluded
patients without a valid deprivation score since this group may
represent a more transient population where follow-up could
be unreliable or unrepresentative. Their deprivation scores are
unlikely to be missing at random so we did not think it would
be appropriate to impute them.
We used an incident user design to help minimise the impact
of the biases that can arise from non-randomised studies such
as in the current study.20 In particular it can help reduce biases
that occur when comparisons include patients who were already
using the drug at the start of the study. An incident user design
also helps to ensure that the analysis captures all events that
occurred after the start of treatment and reduces the chance of
bias that could otherwise occur from patients who stop
treatments as a result of early side effects.20 There is no
consensus on the duration of the treatment-free period before
study entry to classify a patient as a new user. Ray and
colleagues defined incident use of non-steroidal
anti-inflammatory drugs as patients who had not been prescribed
treatment in the 365 days before entry to the cohort.44 We
selected 180 days to help ensure our methods were comparable
to the recently published FDA protocol to assess safety of new
anticoagulants.37
The present validation has been done on a completely separate
set of practices and individuals to those used to develop the
score, although the practices all use the same general practice
clinical computer system (EMIS, the computer system used by
55% of UK general practices). An independent validation study
would be a more stringent test and should be done, but when
such independent studies have examined other risk
algorithms,41 42 45 46 they have shown comparable performance
compared with the validation in the QResearch database.25 38 40
We (or another academic team) intend to conduct a separate
validation on an independent database using a different clinical
system (Clinical Practice Research Datalink, CPRD) as part of
a separate project.
Other limitations of our study were that we measured exposure
to anticoagulants based on prescriptions issued rather than a
more direct measure of adherence to reflect whether the patient
had actually taken the anticoagulants. However, we think it
would be unusual for patients to continue to request repeat
prescriptions for drugs that they are not taking. Also we did not
take account of the degree of anticoagulation achieved during
follow-up by analysing measurements for international
normalised ratios. This was because our intention was to develop
a score that would inform the decision to start anticoagulants,
which would be based on information already available to the
doctor and the patient rather than information that could vary
during follow-up. Other limitations of our study included the
lack of formally adjudicated outcomes, information bias, and
potential for bias due to missing data. Also we included only
two severe haemorrhagic outcomes, but these account for most
types of severe bleed likely to be associated with
anticoagulation. We were unable to include some rarer
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haemorrhagic outcomes since these either do not have ICD
codes or are not routinely recorded in the datasets available to
us.
These QBleed models have been developed using data from
general practices in England and include a postcode related
deprivation score. The models are therefore not likely to be
applicable for clinical use in international settings without some
modification of the English specific risk factors, and validation
in the setting in which they are intended to be used.We included
the Townsend score in the QBleed models since there is a clear
relation between risk of bleeding and deprivation, which is
captured by this variable. If we omitted it, it would tend to
underestimate bleeding risk in patients from deprived areas.
The corresponding QStroke score (which is used to identify
some of those at high risk of stroke who might benefit from
anticoagulation) includes deprivation and so we considered it
would be more consistent to include it in both scores. In terms
of international use of QBleed, where the Townsend score is
not available, a locally relevant deprivation score could be
constructed or adapted for a particular country to have a range
between −11 (affluent) and 7 (deprived) to correspond to the
range of Townsend scores that could be used instead (subject
to local validation).
Conclusion
We developed and validated a set of new algorithms to predict
absolute risk of upper gastrointestinal and intracranial bleed in
new users of anticoagulants. QBleed has some advantages
compared with current risk scoring methods. QBleed also
provides an accurate measure of absolute risk of bleed in the
general population as shown by its performance in a separate
validation cohort. Further research is needed to evaluate the
clinical outcomes and cost effectiveness of using this algorithm
in primary care.
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Tables
Table 1| Characteristics of patients at baseline comparing those not taking any anticoagulant, prescribed warfarin, and prescribed another
type of anticoagulant except for warfarin
Validation cohort (n=1 358 231)Derivation cohort (n=4 378 851)
Characteristics Other anticoagulantWarfarinNo anticoagulantOther anticoagulantWarfarinNo anticoagulant
218 (52.4)6915 (45.5)687 945 (51.2)841 (51.2)23 740 (45.2)22 10 508 (51.1)Female
198 (47.6)8276 (54.5)654 679 (48.8)800 (48.8)28 745 (54.8)2 114 217 (48.9)Male
Age group (years):
11 (2.6)1035 (6.8)747 255 (55.7)57 (3.5)3438 (6.6)2 359 220 (54.6)21-24
65 (15.6)3473 (22.9)379 169 (28.2)301 (18.3)11 810 (22.5)1 252 978 (29.0)45-64
122 (29.3)4029 (26.5)109 989 (8.2)473 (28.8)13 914 (26.5)369 120 (8.5)65-74
143 (34.4)4845 (31.9)71 127 (5.3)544 (33.2)16 932 (32.3)233 567 (5.4)75-84
75 (18.0)1809 (11.9)35 084 (2.6)266 (16.2)6391 (12.2)109 840 (2.5)≥85
−1.2 (3.1)−0.6 (3.3)0.5 (3.6)−1.1 (3.0)−0.7 (3.2)0.3 (3.6)Mean (SD) Townsend score
331 (79.6)12 365 (81.4)10 29 330 (76.7)1281 (78.1)41 687 (79.4)3 200 178 (74.0)Self assigned ethnicity recorded:
408 (98.1)14 713 (96.9)11 70 896 (87.2)1606 (97.9)51 071 (97.3)3 819 953 (88.3)White or not recorded
*99 (0.7)28 242 (2.1)9 (0.5)277 (0.5)91 005 (2.1)Indian
*43 (0.3)17681 (1.3)*112 (0.2)45 597 (1.1)Pakistani
*17 (0.1)11827 (0.9)*63 (0.1)35 891 (0.8)Bangladeshi
*28 (0.2)19131 (1.4)5 (0.3)110 (0.2)62 500 (1.4)Other Asian
*123 (0.8)15367 (1.1)6 (0.4)326 (0.6)42 109 (1.0)Caribbean
*59 (0.4)30583 (2.3)*153 (0.3)79 299 (1.8)Black African
*12 (0.1)11319 (0.8)*42 (0.1)47 733 (1.1)Chinese
*97 (0.6)37578 (2.8)8 (0.5)331 (0.6)100 638 (2.3)Other
413 (99.3)15 179 (99.9)1 294 037 (96.4)1633 (99.5)52 405 (99.8)4 163 230 (96.3)Smoking status recorded (cigarettes/day):
225 (54.1)7661 (50.4)734 433 (54.7)852 (51.9)26 673 (50.8)2 416 565 (55.9)Non-smoker
163 (39.2)5971 (39.3)262 279 (19.5)637 (38.8)20 245 (38.6)806 807 (18.7)Former smoker
16 (3.8)954 (6.3)180 275 (13.4)84 (5.1)3339 (6.4)569 657 (13.2)Light smoker (1-9)
*350 (2.3)74 830 (5.6)39 (2.4)1310 (2.5)238 430 (5.5)Moderate smoker (10-19)
7 (1.7)243 (1.6)42 220 (3.1)21 (1.3)838 (1.6)131 771 (3.0)Heavy smoker (≥20)
379 (91.1)14 314 (94.2)10 88 990 (81.1)1532 (93.4)49 206 (93.8)3 537 384 (81.8)Alcohol status recorded (units/day):
131 (31.5)5426 (35.7)345 074 (25.7)524 (31.9)18 388 (35.0)11 25 701 (26.0)Non-drinker
120 (28.8)4339 (28.6)370 619 (27.6)498 (30.3)15 226 (29.0)12 03 862 (27.8)Trivial (<1)
52 (12.5)1956 (12.9)175 150 (13.0)206 (12.6)6668 (12.7)561 310 (13.0)Light (1 or 2)
69 (16.6)2354 (15.5)177 676 (13.2)275 (16.8)7953 (15.2)579 526 (13.4)Moderate (3-6)
5 (1.2)165 (1.1)12 395 (0.9)21 (1.3)681 (1.3)42 237 (1.0)Heavy (7-9)
*74 (0.5)8076 (0.6)8 (0.5)290 (0.6)24 748 (0.6)Very heavy (>9)
Clinical conditions and drugs:
98 (23.6)3386 (22.3)104 068 (7.8)444 (27.1)12 088 (23.0)348 785 (8.1)Previous bleed
*20 (0.1)960 (0.1)*73 (0.1)3215 (0.1)Oesophageal varices
*156 (1.0)6656 (0.5)16 (1.0)497 (0.9)20 765 (0.5)Chronic liver disease/pancreatitis
41 (9.9)1282 (8.4)36 162 (2.7)123 (7.5)4561 (8.7)118 225 (2.7)Cancer
385 (92.5)13 619 (89.7)642 051 (47.8)1527 (93.1)47 435 (90.4)21 31 904 (49.3)Platelets recorded
23 (5.5)944 (6.2)20 268 (1.5)89 (5.4)3416 (6.5)66 414 (1.5)Most recent platelet <150/μL or >480/μL
151 (36.3)5625 (37.0)95 597 (7.1)568 (34.6)19 472 (37.1)314 857 (7.3)Antiplatelet drug
162 (38.9)4091 (26.9)203 539 (15.2)640 (39.0)14 349 (27.3)701 062 (16.2)NSAIDS
41 (9.9)1812 (11.9)39 394 (2.9)162 (9.9)6009 (11.4)136776 (3.2)Corticosteroids
83 (20.0)2849 (18.8)149 439 (11.1)290 (17.7)9627 (18.3)488 308 (11.3)Antidepressants
*163 (1.1)6962 (0.5)10 (0.6)575 (1.1)22 332 (0.5)Phenytoin or carbamazepine
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Table 1 (continued)
Validation cohort (n=1 358 231)Derivation cohort (n=4 378 851)
Characteristics Other anticoagulantWarfarinNo anticoagulantOther anticoagulantWarfarinNo anticoagulant
76 (18.3)1794 (11.8)10 690 (0.8)189 (11.5)6391 (12.2)33 099 (0.8)Atrial fibrillation
17 (4.1)1253 (8.2)13 388 (1.0)70 (4.3)4426 (8.4)42 072 (1.0)Venous thromboembolism
16 (3.8)740 (4.9)8891 (0.7)54 (3.3)2582 (4.9)28 071 (0.6)Congestive cardiac failure
186 (44.7)6654 (43.8)143 734 (10.7)685 (41.7)22 507 (42.9)473 972 (11.0)Treated hypertension
377 (90.6)13 855 (91.2)1 035 111 (77.1)1519 (92.6)47 865 (91.2)3 328 834 (77.0)Body mass index recorded
28.2 (5.2)28.5 (5.2)25.9 (4.8)28.3 (5.1)28.4 (5.2)26 (4.8)Mean (SD) body mass index
NSAIDS=non-steroidal anti-inflammatory drugs.
*Counts <5 have been suppressed.
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Table 2| Incident haemorrhagic events in derivation cohort recorded on mortality or hospital records
Age standardised incidence rate per 1000 person years* (95% CI)Person yearsCases on mortality or hospital dataHaemorrhagic events
Upper gastrointestinal bleed:
1.34 (1.32 to 1.36)16 332 68421 143No anticoagulants
5.83 (4.33 to 7.33)71 597492Warfarin
2.69 (0.36 to 5.03)6646New anticoagulants
Intracranial bleed:
0.55 (0.54 to 0.56)16 332 6848 670No anticoagulants
1.89 (1.46 to 2.32)71 597365Warfarin
1.49 (1.27 to 2.86)6645New anticoagulants
*Age standardised to derivation cohort population.
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Table 3| Adjusted hazard ratios (95% confidence intervals) in derivation cohort for upper gastrointestinal haemorrhagic events recorded
on mortality or hospital records
Adjusted hazard ratio*(95% CI)
Characteristics MenWomen
1.17 (1.13 to 1.20)1.11 (1.08 to 1.15)Townsend score (5 unit increase)
Smoking status (cigarettes/day):
11Non-smoker
1.12 (1.07 to 1.18)1.09 (1.04 to 1.14)Former smoker
1.40 (1.33 to 1.49)1.31 (1.23 to 1.40)Light smoker (1-9)
1.39 (1.28 to 1.52)1.30 (1.19 to 1.43)Moderate smoker (10-19)
1.62 (1.48 to 1.76)1.56 (1.39 to 1.74)Heavy smoker (≥20)
Ethnicity:
11White or ethnicity not recorded
0.97 (0.82 to 1.14)0.96 (0.80 to 1.16)Indian
0.82 (0.65 to 1.04)0.99 (0.76 to 1.28)Pakistani
0.94 (0.74 to 1.19)0.88 (0.65 to 1.19)Bangladeshi
0.95 (0.75 to 1.19)0.81 (0.62 to 1.06)Other Asian
1.11 (0.92 to 1.33)1.14 (0.95 to 1.36)Caribbean
0.85 (0.69 to 1.05)0.54 (0.41 to 0.72)Black African
0.91 (0.66 to 1.26)1.05 (0.77 to 1.44)Chinese
0.94 (0.79 to 1.11)1.04 (0.87 to 1.24)Other
Alcohol intake (units/day):
11None
0.82 (0.78 to 0.86)0.87 (0.83 to 0.92)Trivial (<1)
0.82 (0.77 to 0.87)0.79 (0.74 to 0.85)Light (1-2)
0.89 (0.85 to 0.95)0.99 (0.92 to 1.07)Moderate (3-6)
1.35 (1.21 to 1.50)1.85 (1.47 to 2.32)Heavy (7-9)
1.79 (1.57 to 2.04)2.85 (2.27 to 3.59)Very heavy (>9)
Clinical conditions†:
2.11 (1.98 to 2.26)2.26 (2.10 to 2.43)Previous bleed
2.07 (1.59 to 2.68)3.35 (2.58 to 4.33)Oesophageal varices
3.08 (2.75 to 3.45)2.81 (2.44 to 3.23)Chronic liver disease/pancreatitis
1.21 (1.07 to 1.36)1.24 (1.11 to 1.39)Atrial fibrillation
1.12 (0.98 to 1.28)1.16 (1.04 to 1.30)Venous thromboembolism
1.46 (1.30 to 1.64)1.41 (1.25 to 1.59)Congestive cardiac failure
1.11 (1.05 to 1.16)1.06 (1.01 to 1.12)Treated hypertension
1.39 (1.29 to 1.50)1.22 (1.13 to 1.31)Cancer
1.79 (1.64 to 1.96)1.68 (1.52 to 1.85)Most recent platelet count <150/μL or >480/μL
Drugs†:
4.43 (3.32 to 5.92)3.89 (2.75 to 5.49)Anticoagulant
1.21 (1.15 to 1.28)1.26 (1.19 to 1.33)Antiplatelet drug
1.09 (1.05 to 1.14)1.16 (1.11 to 1.21)NSAIDS
1.26 (1.17 to 1.36)1.26 (1.18 to 1.34)Corticosteroids
1.69 (1.60 to 1.78)1.57 (1.51 to 1.64)Antidepressants
1.30 (1.10 to 1.55)1.40 (1.18 to 1.65)Phenytoin or carbamazepine
NSAIDS=non-steroidal anti-inflammatory drugs.
Models also included fractional polynomial terms for age and body mass index.
Fractional polynomial terms for women were (age/10)−1 and (age/10)3; (body mass index/10)−2 and (body mass index/10)−2 ln(body mass index). Fractional polynomial
terms for men were (age/10)−1 and (age/10)3 ln(age); (body mass index/10)−2 and (body mass index/10)−2 ln(body mass index).
The models for men and women also included interactions between the age terms and anticoagulant use and between age and previous bleed. Hazard ratios for
these variables in the table are evaluated at mean age in men and women.
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Table 3 (continued)
Adjusted hazard ratio*(95% CI)
Characteristics MenWomen
*Hazard ratios simultaneously adjusted for all other variables shown in table as well as for fractional polynomial terms for age and body mass index.
†Compared with patients without condition or drug at baseline.
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Table 4| Adjusted hazard ratios (95% confidence interval) in the derivation cohort for intracranial haemorrhagic events recorded onmortality
or hospital records
Adjusted hazard ratio* (95% CI)
Characteristics MenWomen
1.12 (1.07 to 1.17)1.15 (1.10 to 1.20)Townsend score (5 unit increase)
Smoking status (cigarettes/day):
11Non-smoker
1.04 (0.97 to 1.12)1.12 (1.04 to 1.21)Former smoker
1.44 (1.31 to 1.58)1.80 (1.63 to 1.99)Light smoker (1-9)
1.72 (1.50 to 1.97)2.12 (1.86 to 2.43)Moderate smoker (10-19)
1.72 (1.47 to 2.00)2.37 (2.01 to 2.81)Heavy smoker (≥20)
Ethnicity:
11White or not recorded
1.08 (0.82 to 1.42)1.02 (0.73 to 1.42)Indian
1.02 (0.69 to 1.52)0.92 (0.52 to 1.63)Pakistani
1.15 (0.76 to 1.73)1.60 (1.00 to 2.56)Bangladeshi
1.44 (1.03 to 2.03)0.94 (0.58 to 1.52)Other Asian
1.32 (1.01 to 1.72)1.14 (0.84 to 1.56)Caribbean
1.56 (1.16 to 2.11)1.20 (0.80 to 1.80)Black African
1.15 (0.66 to 1.98)1.43 (0.84 to 2.42)Chinese
1.02 (0.75 to 1.38)1.14 (0.83 to 1.56)Other
Alcohol intake (units/day):
11None
0.84 (0.77 to 0.92)0.96 (0.89 to 1.03)Trivial (<1)
0.85 (0.77 to 0.93)1.03 (0.92 to 1.16)Light (1-2)
0.97 (0.88 to 1.06)1.05 (0.93 to 1.18)Moderate (3-6)
1.58 (1.34 to 1.86)2.13 (1.49 to 3.03)Heavy (7-9)
1.48 (1.14 to 1.92)2.62 (1.73 to 3.97)Very heavy (>9)
Clinical conditions†:
1.32 (1.23 to 1.42)1.33 (1.23 to 1.44)Previous bleed
1.72 (1.01 to 2.91)3.22 (2.07 to 5.01)Oesophageal varices
2.21 (1.79 to 2.73)1.92 (1.50 to 2.46)Chronic liver disease or pancreatitis
1.36 (1.18 to 1.57)1.17 (1.01 to 1.35)Atrial fibrillation
1.18 (1.09 to 1.26)1.06 (1.00 to 1.14)Treated hypertension
1.61 (1.41 to 1.83)1.62 (1.41 to 1.88)Most recent platelet count <150/μL or >480/μL
Drugs†:
3.99 (1.86 to 8.55)3.62 (1.25 to 10.49)Anticoagulant
1.27 (1.17 to 1.36)1.31 (1.22 to 1.41)Antiplatelet drug
1.38 (1.27 to 1.50)1.31 (1.22 to 1.40)Antidepressants
2.03 (1.64 to 2.53)2.20 (1.79 to 2.70)Phenytoin or carbamazepine
NSAIDS=non-steroidal anti-inflammatory drugs.
Models also included fractional polynomial terms for age and body mass index.
Fractional polynomial terms for women were (age/10)−1 and (age/10)3; (body mass index/10)−2 and (body mass index/10)−2 ln(body mass index). Fractional polynomial
terms for men were (age/10)−1 and (age/10)3 ln(age); (body mass index/10)−2 and (body mass index/10)−2 ln(body mass index).
The models for men and women also included interactions between the age terms and anticoagulant use. Hazard ratios for these variables in the table are evaluated
at mean age in men and women.
*Hazard ratios simultaneously adjusted for all other variables shown in table as well as for fractional polynomial terms for age and body mass index.
†Compared with patients without condition or drug at baseline.
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Table 5| Performance of each algorithm in validation cohort using incident events included in hospital or mortality data
Mean (95% CI)
Incident events MenWomen
Upper gastrointestinal bleed:
0.747 (0.738 to 0.756)0.766 (0.758 to 0.775)ROC statistic*
36.9 (35.1 to 38.7)40.7 (38.9 to 42.6)R2 (%)†
1.57 (1.51 to 1.63)1.70 (1.63 to 1.76)D statistic‡
Intracranial bleed:
0.812 (0.80 to 0.824)0.847 (0.838 to 0.856)ROC statistic*
53.3 (51.1 to 55.4)58.0 (56.0 to 60.0)R2 (%)†
2.19 (2.09 to 2.28)2.40 (2.30 to 2.50)D statistic‡
Discrimination is ability of risk prediction model to differentiate between patients who do and do not experience an event during the study.
*Receiver operating characteristic (ROC) curve statistic; higher values indicate better discrimination.
†Measures explained variation, with higher values indicating more variation explained.
‡Measure of discrimination specific to censored survival data. As with ROC, higher values indicate better discrimination.
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Table 6| Performance of each model in the validation cohort based on top 10% of patients at highest risk (n=135 823 patients). Values are
point estimates (95% confidence intervals)
Observed risk* at 5
years (%)
Positive likelihood
ratio
Negative predictive
value (%)Specificity (%)Sensitivity (%)
Cut-off 5 year
risk (%)Events
2.70 (2.60 to 2.80)3.85 (3.83 to 3.97)99.67 (99.65 to 99.68)90.14 (90.09 to 90.19)38.0 (36.81 to 39.17)1.4Upper
gastrointestinal
bleed
1.50 (1.45 to 1.62)5.15 (4.96 to 5.34)99.89 (99.88 to 99.89)90.09 (90.03 to 90.14)51.03 (49.17 to 52.89)0.7Intracranial bleed
*Estimate of positive predictive value.
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Figures
Fig 1 Graphs showing fractional polynomial terms for age (hazard ratios compared with age 40) and body mass index
(hazard ratios compared with body mass index 25) and age interactions for upper gastrointestinal bleed
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Fig 2 Graphs showing fractional polynomial terms for age (hazard ratios compared with age 40) and body mass index
(hazard ratios compared with body mass index 25) and interaction between anticoagulant use and age for intracranial bleed
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Fig 3Mean predicted risks and observed risks at five years by 10th of predicted risk applying QBleed risk prediction scores
to all patients in QResearch validation cohort
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Fig 4 Example of risk of bleed with and without anticoagulants in two patients using the web calculator at www.qbleed.org
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